Dian Diagnostics Group Co.,Ltd.
SZSE:300244.SZ
22 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 13,362.282 | 20,282.469 | 13,082.613 | 10,649.162 | 8,453.207 | 6,966.857 | 5,004.124 | 3,823.981 | 1,858.181 | 1,335.1 | 1,015.474 | 706.419 | 482.474 | 343.273 | 263.253 | 178.29 |
Cost of Revenue
| 9,304.867 | 12,745.811 | 8,076.949 | 6,578.706 | 5,735.399 | 4,595.1 | 3,332.134 | 2,619.637 | 1,233.461 | 847.784 | 638.651 | 454.143 | 314.211 | 220.299 | 170.167 | 125.686 |
Gross Profit
| 4,057.414 | 7,536.659 | 5,005.664 | 4,070.456 | 2,717.808 | 2,371.757 | 1,671.99 | 1,204.344 | 624.72 | 487.316 | 376.823 | 252.276 | 168.263 | 122.974 | 93.086 | 52.605 |
Gross Profit Ratio
| 0.304 | 0.372 | 0.383 | 0.382 | 0.322 | 0.34 | 0.334 | 0.315 | 0.336 | 0.365 | 0.371 | 0.357 | 0.349 | 0.358 | 0.354 | 0.295 |
Reseach & Development Expenses
| 398.062 | 638.474 | 424.749 | 319.104 | 211.911 | 166.265 | 131.965 | 101.162 | 78.182 | 57.014 | 33.353 | 22.551 | 10.656 | 0 | 0 | 0 |
General & Administrative Expenses
| 180.351 | 270.882 | 227.778 | 205.658 | 196.051 | 187.387 | 167.377 | 118.525 | 74.151 | 55.706 | 44.101 | 32.715 | 28.431 | 53.204 | 43.818 | 21.152 |
Selling & Marketing Expenses
| 1,398.112 | 1,597.087 | 1,210.426 | 966.374 | 760.775 | 648.651 | 464.185 | 326.827 | 164.115 | 134.381 | 115.842 | 79.114 | 50.168 | 33.428 | 24.102 | 16.448 |
SG&A
| 2,661.158 | 1,867.969 | 1,438.204 | 1,172.032 | 956.826 | 836.038 | 631.562 | 445.352 | 238.266 | 190.087 | 159.942 | 111.83 | 78.599 | 86.632 | 67.92 | 37.6 |
Other Expenses
| -0.063 | 961.484 | 861.911 | 564.857 | 464.438 | 12.676 | 36.583 | 19.102 | 16.301 | 2.698 | 3.617 | -3.028 | 2.697 | 4.113 | 0.718 | -0.478 |
Operating Expenses
| 3,059.283 | 3,467.926 | 2,724.864 | 2,055.993 | 1,633.175 | 1,446.616 | 1,115.625 | 789.393 | 430.244 | 339.196 | 268.003 | 184.019 | 125.542 | 88.041 | 70.398 | 42.249 |
Operating Income
| 998.132 | 3,814.966 | 1,837.935 | 2,077.021 | 1,192.446 | 721.398 | 592.902 | 415.852 | 194.54 | 150.217 | 108.229 | 71.596 | 46.425 | 33.859 | 19.271 | 6.975 |
Operating Income Ratio
| 0.075 | 0.188 | 0.14 | 0.195 | 0.141 | 0.104 | 0.118 | 0.109 | 0.105 | 0.113 | 0.107 | 0.101 | 0.096 | 0.099 | 0.073 | 0.039 |
Total Other Income Expenses Net
| -193.084 | -1,271.403 | -46.938 | -759.625 | -421.271 | -191.067 | 73.121 | 19.402 | 15.981 | 4.19 | 2.829 | 5.003 | 6.265 | 2.927 | -2.73 | -3.883 |
Income Before Tax
| 805.048 | 2,543.562 | 1,790.997 | 1,317.395 | 771.175 | 734.074 | 629.486 | 434.353 | 210.457 | 152.31 | 111.649 | 73.26 | 48.986 | 37.861 | 19.958 | 6.472 |
Income Before Tax Ratio
| 0.06 | 0.125 | 0.137 | 0.124 | 0.091 | 0.105 | 0.126 | 0.114 | 0.113 | 0.114 | 0.11 | 0.104 | 0.102 | 0.11 | 0.076 | 0.036 |
Income Tax Expense
| 216.735 | 681.092 | 307.396 | 247.461 | 195.607 | 145.612 | 165.394 | 96.403 | 31.671 | 24.457 | 21.615 | 13.866 | 7.406 | 7.946 | 4.74 | 1.968 |
Net Income
| 307.461 | 1,434.191 | 1,162.884 | 802.933 | 575.568 | 388.608 | 349.593 | 262.761 | 174.795 | 124.584 | 86.093 | 60.188 | 42.208 | 32.411 | 17.169 | 6.59 |
Net Income Ratio
| 0.023 | 0.071 | 0.089 | 0.075 | 0.068 | 0.056 | 0.07 | 0.069 | 0.094 | 0.093 | 0.085 | 0.085 | 0.087 | 0.094 | 0.065 | 0.037 |
EPS
| 0.5 | 2.3 | 1.87 | 1.29 | 0.93 | 0.71 | 0.64 | 0.48 | 0.36 | 0.26 | 0.18 | 0.13 | 0.1 | 0.096 | 0.065 | 0.028 |
EPS Diluted
| 0.5 | 2.3 | 1.87 | 1.29 | 0.93 | 0.71 | 0.64 | 0.48 | 0.36 | 0.26 | 0.18 | 0.13 | 0.1 | 0.096 | 0.065 | 0.028 |
EBITDA
| 1,790.106 | 4,614.465 | 2,789.156 | 2,369.931 | 1,440.146 | 1,186.681 | 908.488 | 540.067 | 272.763 | 184.097 | 135.759 | 90.87 | 58.742 | 46.065 | 29.111 | 13.855 |
EBITDA Ratio
| 0.134 | 0.228 | 0.213 | 0.223 | 0.17 | 0.17 | 0.182 | 0.141 | 0.147 | 0.138 | 0.134 | 0.129 | 0.122 | 0.134 | 0.111 | 0.078 |